Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | ACACA | Q13085 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372643 | 1.00 | GPR119 (0.39) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2217076 | 0.93 | GPR119 (0.40) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2217078 | 0.93 | GPR119 (0.40) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL12434725 | 0.93 | GPR119 (0.37) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2215967 | 0.92 | GPR119 (0.36) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2371250 | 0.90 | GPR119 (0.42) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2218046 | 0.90 | GPR119 (0.39) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2218048 | 0.90 | GPR119 (0.39) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL14137934 | 0.89 | GPR119 (0.41) | GPR119ACACBACACARAB9ANPC1 | |
| SCHEMBL2372242 | 0.89 | ACACB (0.42) | GPR119ACACBACACARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | claimed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2114931-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | GPR119 1/4885ACACB 3197/4885ACACA 2646/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885ACACB 1754/4885ACACA 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.